SCHEMBL12266572

SCHEMBL12266572

Brc1ccc2ncc3nn(Cc4ccccc4)c(Br)c3c2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 5/20 0.43
▸ LMNA P02545 4/20 0.43
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ CCNC P24863 1/20 0.41
▸ CDK8 P49336 1/20 0.41
▸ GABRA1 P14867 1/20 0.41
▸ GABRG2 P18507 1/20 0.41
▸ GABRB3 P28472 1/20 0.41
▸ GABRA5 P31644 1/20 0.41
▸ GABRA3 P34903 1/20 0.41
▸ GABRA2 P47869 1/20 0.41
▸ GABRA6 Q16445 1/20 0.41
▸ PIK3CD O00329 1/20 0.41
▸ PIK3R1 P27986 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ KMT2A Q03164 5/20 0.40
▸ MEN1 O00255 4/20 0.40
▸ MAPT P10636 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ GALR3 O60755 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1559545 0.81 LMNA (0.42) HTTLMNASMN1; SMN2CCNCCDK8
SCHEMBL1558910 0.76 LMNA (0.45) HTTLMNASMN1; SMN2CCNCCDK8
SCHEMBL1558176 0.75 RECQL (0.46) HTTLMNASMN1; SMN2CCNCCDK8
SCHEMBL2395512 0.73 HTT (0.51) HTTLMNAHIF1AKMT2AMAPT
SCHEMBL2394787 0.72 PKM (0.47) HTTLMNASMN1; SMN2KMT2AMEN1
SCHEMBL1170105 0.71 CYP1A2 (0.50) HTTKMT2AMEN1MAPTALDH1A1
SCHEMBL14312337 0.69 KMT2A (0.51) HTTLMNASMN1; SMN2KMT2AMEN1
SCHEMBL2399011 0.68 GABRA1 (0.40) HTTLMNASMN1; SMN2CCNCCDK8
SCHEMBL29723994 0.67 GRK2 (0.65) —
SCHEMBL27826048 0.67 XDH (0.45) HTTLMNASMN1; SMN2HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PROGENICS PHARMACEUTICALS, INC. 2011-09-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110212053-A1 PHOSPHATIDYLINOSITOL 3 KINASE INHIBITORS PIK3CA, AKT1, PIK3R5 HTT 2663/4885LMNA 2658/4885SMN1; SMN2 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback